Ligandal

Capability Statement

CAGE Code: 7CEN1 | www.ligandal.com | **DUNS Number:** 079457246

Ligandal, Inc. has spent 9 years developing peptide-based delivery technologies for gene therapy, gene editing, regenerative medicine, immunotherapy, and advanced vaccine technologies. We have nearly 10 years of experience, various credentials, and offer an array of specializations. Our solutions include but are not limited to: pandemic preparedness, cell-specificity, gene editing, regenerative medicine, and immunotherapy. In addition to our vast skill set, we consistently develop new therapeutic candidates and have created the first peptide-based delivery system that led to gene editing of immune cells with CRISPR. We also built the first delivery system for gene editing a live mouse with a peptide-based system in 2013. At Ligandal, our team of professionals successfully deliver tailored gene therapy approaches, new vaccines, technologies, and more. Please contact us today for additional information on our company and federal contracting abilities.

Core Competencies

Rapid Simulation & Synthetic Peptide Mini-Scaffold Vaccine Designing

Coronavirus (SARS-COV-2) Pandemic Preparedness

Additional Peptide-Based Delivery Technologies Services

Cell Specificity
Gene Therapy
Gene Editing
Computational Modeling
Regenerative Medicine
Immunotherapy
Advanced Vaccine Technologies

Contact Information

Andre Watson
CEO & Chairman
(978) 496-4635
dre@ligandal.com

650 5th Street Suite 311
San Francisco, CA 94107

Differentiators

- In business since 2014
- 9 years of biotechnology experience
- Currently developing a set of proprietary immunotherapies and hematological gene therapies
- Building a computationally driven predictive modeling capability for rapidly developing ultra-specific
- Targeting agents for delivering to or modulating any cell type or physiological trait
- Flexibly to deliver range of protein payloads and nucleic acids to specific cellular or protein targets
- Target specific cells
- Nucleus of cell
- Release CRISPR or RNA reprogramming payload

NAICS Codes

541713, 541715, 541714, 325414, 325412, 541690

Past Performance

Developed first peptide-based delivery system that led to gene editing of immune cells

Built predictive modeling for designing peptides that stick to specific proteins

Fully integrated laboratory in 30 days after receiving funds, utilizing series of fully automated instruments to perform full-scale synthesis and characterization of various development candidates

Received letters of understanding and intent from numerous groups including Celgene and other gene-editing, immunotherapy and gene therapy companies

Horizon 2020, UK - initiated materials transfer regarding services above - $65 billion European Project
Rubius - initiated discovery program for red blood cell reprogramming